Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers

Archives of General Psychiatry

Volumn 68, Issue 5, 2011, Pages 505-515

  Culbertson, Christopher S ^a   Bramen, Jennifer ^a   Cohen, Mark S ^a   London, Edythe D ^a,b   Olmstead, Richard E ^c   Gan, Joanna J ^a   Costello, Matthew R ^a   Shulenberger, Stephanie ^c   Mandelkern, Mark A ^c,d   Brody, Arthur L ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; PLACEBO;

ADULT; ANTERIOR CINGULATE; ARTICLE; ASSOCIATION; CIGARETTE SMOKING; CLINICAL ARTICLE; CORPUS STRIATUM; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LIMBIC CORTEX; MALE; ORBITAL CORTEX; OXYGEN BLOOD LEVEL; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN MAPPING; BUPROPION; CUES; DOMINANCE, CEREBRAL; DOUBLE-BLIND METHOD; FEMALE; FRONTAL LOBE; GYRUS CINGULI; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIMBIC SYSTEM; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTIVATION; PREFRONTAL CORTEX; SMOKING; SMOKING CESSATION; TEMPORAL LOBE; TOBACCO USE DISORDER;

EID: 79951692178     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2010.193     Document Type: Article

References (92)

1. Raw M, Regan S, Rigotti NA, McNeill A. A survey of tobacco dependence treatment guidelines in 31 countries. Addiction. 2009;104(7):1243-1250.
2. Holmes S, Zwar N, Jiménez-Ruiz CA, Ryan PJ, Browning D, Bergmann L, Johnston JA. Bupropion as an aid to smoking cessation: a review of real-life effectiveness. Int J Clin Pract. 2004;58(3):285-291. (Pubitemid 38559527)
3. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17):1195-1202. (Pubitemid 27454451)
4. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685-691. (Pubitemid 29110752)
5. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med. 2001;135(6):423-433. (Pubitemid 32845867)
6. Durcan MJ, Deener G, White J, Johnston JA, Gonzales D, Niaura R, Rigotti N, Sachs DP. The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clin Ther. 2002;24(4):540-551. (Pubitemid 34492876)
7. Paluck EC, McCormack JP, Ensom MH, Levine M, Soon JA, Fielding DW. Outcomes of bupropion therapy for smoking cessation during routine clinical use. Ann Pharmacother. 2006;40(2):185-190. (Pubitemid 43269845)
8. Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. Arch Intern Med. 2004;164(16):1797-1803. (Pubitemid 39215652)
9. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl). 2000;148(1):33-40. (Pubitemid 30062470)
10. Strong DR, Kahler CW, Leventhal AM, Abrantes AM, Lloyd-Richardson E, Niaura R, Brown RA. Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. Nicotine Tob Res. 2009;11(10):1142-1153.
11. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA. 2002;288(4):468-474. (Pubitemid 34787478)
12. Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction. 2004;99(9):1206-1218. (Pubitemid 39215283)
13. Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, Samuels D, Levin SK, Green S, Schatzberg AF. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol. 2004;72(4):729-735. (Pubitemid 38988850)
14. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, Bergman K. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med. 2003;163(19):2337-2344. (Pubitemid 37310195)
15. Tønnesen P, Tonstad S, Hjalmarson A, Lebargy F, Van Spiegel PI, Hider A, Sweet R, Townsend J. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med. 2003;254(2):184-192. (Pubitemid 36900442)
16. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395-401.
17. Balfour DJ. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract. 2001;55(1):53-57.
18. Bondarev ML, Bondareva TS, Young R, Glennon RA. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol. 2003;474(1):85-93. (Pubitemid 37289149)
19. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology. 1994;11(2):133-141.
20. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol. 2004;66(3):675-682. (Pubitemid 39329267)
21. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006;6(9):1249-1265. (Pubitemid 44580948)
22. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology. 1989;2(4):273-279. (Pubitemid 20025254)
23. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166.
24. Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, La°ngstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54(8):800-805.
25. Mansvelder HD, Mertz M, Role LW. Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits. Semin Cell Dev Biol. 2009;20(4):432-440.
26. Markou A. Neurobiology of nicotine dependence [review]. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507):3159-3168.
27. Alkondon M, Albuquerque EX. Nicotinic receptor subtypes in rat hippocampal slices are differentially sensitive to desensitization and early in vivo functional up-regulation by nicotine and to block by bupropion. J Pharmacol Exp Ther. 2005;313(2):740-750. (Pubitemid 40604175)
28. Arias HR. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol. 2009;41(11):2098-2108.
29. Dwoskin LP, Smith AM, Wooters TE, Zhang Z, Crooks PA, Bardo MT. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol. 2009;78(7):732-743. doi:10.1016/j.bcp.2009.06.002.
30. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther. 1999;288(1):88-92. (Pubitemid 29113477)
31. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295(1):321-327.
32. Mansvelder HD, Fagen ZM, Chang B, Mitchum R, McGehee DS. Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochem Pharmacol. 2007;74(8):1283-1291. (Pubitemid 47417936)
33. Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict Biol. 2005;10(3):219-231.
34. Chiamulera C, Borgo C, Falchetto S, Valerio E, Tessari M. Nicotine reinstatement of nicotine self-administration after long-term extinction. Psychopharmacology (Berl). 1996;127(2):102-107. (Pubitemid 26298006)
35. Rose JE, Behm FM. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob Res. 2004;6(3):523-532. (Pubitemid 38967541)
36. Rose JE, Behm FM,Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res. 2006;8(1):89-101.
37. Abrams DB, Monti PM, Carey KB, Pinto RP, Jacobus SI. Reactivity to smoking cues and relapse: two studies of discriminant validity. Behav Res Ther. 1988;26(3):225-233.
38. Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, Hoffman A, Perkins KA, Sved AF. Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav. 2001;70(4):515-530. (Pubitemid 34131646)
39. Caggiula AR, Donny EC, Palmatier MI, Liu X, Chaudhri N, Sved AF. The role of nicotine in smoking: a dual-reinforcement model. Nebr Symp Motiv. 2009;55:91-109.
40. Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG, Ho ML, Saxena S, Baxter LR Jr, Madsen D, Jarvik ME. Brain metabolic changes during cigarette craving. Arch Gen Psychiatry. 2002;59(12):1162-1172. (Pubitemid 35424027)
41. Due DL, Huettel SA, Hall WG, Rubin DC. Activation in mesolimbic and visuospatial neural circuits elicited by smoking cues: evidence from functional magnetic resonance imaging. Am J Psychiatry. 2002;159(6):954-960. (Pubitemid 34586940)
42. Lee JH, Lim Y, Wiederhold BK, Graham SJ. A functional magnetic resonance imaging (FMRI) study of cue-induced smoking craving in virtual environments. Appl Psychophysiol Biofeedback. 2005;30(3):195-204. (Pubitemid 41355723)
43. Wang Z, Faith M, Patterson F, Tang K, Kerrin K, Wileyto EP, Detre JA, Lerman C. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. J Neurosci. 2007;27(51):14035-14040. (Pubitemid 351377866)
44. David SP, Munafò MR, Johansen-Berg H, Smith SM, Rogers RD, Matthews PM, Walton RT. Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study. Biol Psychiatry. 2005;58(6):488-494. (Pubitemid 41393611)
45. Franklin TR, Wang Z, Wang J, Sciortino N, Harper D, Li Y, Ehrman R, Kampman K, O'Brien CP, Detre JA, Childress AR. Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology. 2007;32(11):2301-2309. (Pubitemid 47587682)
46. McClernon FJ, Kozink RV, Rose JE. Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. Neuropsychopharmacology. 2008;33(9):2148-2157. (Pubitemid 351992088)
47. Smolka MN, Bühler M, Klein S, Zimmermann U, Mann K, Heinz A, Braus DF. Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology (Berl). 2006;184(3-4):577-588. (Pubitemid 43255874)
48. Yalachkov Y, Kaiser J, Naumer MJ. Brain regions related to tool use and action knowledge reflect nicotine dependence. J Neurosci. 2009;29(15):4922-4929.
49. Gloria R, Angelos L, Schaefer HS, Davis JM, Majeskie M, Richmond BS, Curtin JJ, Davidson RJ, Baker TB. An fMRI investigation of the impact of withdrawal on regional brain activity during nicotine anticipation. Psychophysiology. 2009;46(4):681-693.
50. McClernon FJ, Hiott FB, Huettel SA, Rose JE. Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues. Neuropsychopharmacology. 2005;30(10):1940-1947. (Pubitemid 41486419)
51. McClernon FJ, Kozink RV, Lutz AM, Rose JE. 24-h smoking abstinence potentiates fMRI-BOLD activation to smoking cues in cerebral cortex and dorsal striatum. Psychopharmacology (Berl). 2009;204(1):25-35.
52. McBride D, Barrett SP, Kelly JT, Aw A, Dagher A. Effects of expectancy and abstinence on the neural response to smoking cues in cigarette smokers: an fMRI study. Neuropsychopharmacology. 2006;31(12):2728-2738. (Pubitemid 44764169)
53. Wilson SJ, Sayette MA, Delgado MR, Fiez JA. Instructed smoking expectancy modulates cue-elicited neural activity: a preliminary study. Nicotine Tob Res. 2005;7(4):637-645. (Pubitemid 41600919)
54. Franklin TR, Lohoff FW, Wang Z, Sciortino N, Harper D, Li Y, Jens W, Cruz J, Kampman K, Ehrman R, Berrettini W, Detre JA, O'Brien CP, Childress AR. DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology. 2009;34(3):717-728.
55. Azizian A, Monterosso J, O'Neill J, London ED. Magnetic resonance imaging studies of cigarette smoking. Handb Exp Pharmacol. 2009;(192):113-143.
56. Le Foll B, Goldberg SR. Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl). 2006;184(3-4):367- 381. (Pubitemid 43255853)
57. Shoaib M, Sidhpura N, Shafait S. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl). 2003;165(4):405-412. (Pubitemid 36223082)
58. Brody AL, Mandelkern MA, Lee G, Smith E, Sadeghi M, Saxena S, Jarvik ME, London ED. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res. 2004;130(3):269-281.
59. Costello MR, Mandelkern MA, Shoptaw S, et al. Effects of treatment for tobacco dependence on resting cerebral glucose metabolism. Neuropsychopharmacology. 2009;35(3):605-612.
60. Weinstein A, Greif J, Yemini Z, Lerman H, Weizman A, Even-Sapir E. Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion [published online July 31, 2009]. J Psychopharmacol. doi:10.1177/0269881109105456.
61. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, version 2.0). New York, NY: New York State Psychiatric Institute; 1995.
62. Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3(3-4):235-241. (Pubitemid 9098397)
63. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict. 1991;86(9):1119-1127.
64. Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL. Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav. 2000;66(3):553-558. (Pubitemid 30440849)
65. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296.
66. Snaith RP, Bridge GW, Hamilton M. The Leeds scales for the self-assessment of anxiety and depression. Br J Psychiatry. 1976;128:156-165.
67. Marrone GF, Paulpillai M, Evans RJ, Singleton EG, Heishman SJ. Breath carbon monoxide and semiquantitative saliva cotinine as biomarkers for smoking. Hum Psychopharmacol. 2010;25(1):80-83.
68. Wald NJ, Idle M, Boreham J, Bailey A. Carbon monoxide in breath in relation to smoking and carboxyhaemoglobin levels. Thorax. 1981;36(5):366-369. (Pubitemid 11105830)
69. Schuh KJ, Stitzer ML. Desire to smoke during spaced smoking intervals. Psychopharmacology (Berl). 1995;120(3):289-295.
70. Brody AL, Mandelkern MA, Olmstead RE, Jou J, Tiongson E, Allen V, Scheibal D, London ED, Monterosso JR, Tiffany ST, Korb A, Gan JJ, Cohen MS. Neural substrates of resisting craving during cigarette cue exposure. Biol Psychiatry. 2007;62(6):642-651. (Pubitemid 47314371)
71. Conklin CA, Tiffany ST. The impact of imagining personalized versus standardized urge scenarios on cigarette craving and autonomic reactivity. Exp Clin Psychopharmacol. 2001;9(4):399-408. (Pubitemid 33117491)
72. Rosenberg H. Clinical and laboratory assessment of the subjective experience of drug craving. Clin Psychol Rev. 2009;29(6):519-534.
73. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5(2):143-156. (Pubitemid 35282800)
74. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17(3):143-155. (Pubitemid 35253488)
75. Woolrich MW, Ripley BD, Brady M, Smith SM. Temporal autocorrelation in univariate linear modeling of FMRI data. Neuroimage. 2001;14(6):1370-1386. (Pubitemid 33124185)
76. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17(2):825-841. (Pubitemid 35317016)
77. Beckmann CF, Jenkinson M, Smith SM. General multilevel linear modeling for group analysis in FMRI. Neuroimage. 2003;20(2):1052-1063. (Pubitemid 37268124)
78. Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage. 2004;21(4):1732-1747. (Pubitemid 38446594)
79. Woolrich MW, Jbabdi S, Patenaude B, Chappell M, Makni S, Behrens T, Beckmann C, Jenkinson M, Smith SM. Bayesian analysis of neuroimaging data in FSL. Neuroimage. 2009;45(1)(suppl):S173-S186.
80. Worsley KJ, Evans AC, Marrett S, Neelin P. A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab. 1992;12(6):900-918.
81. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005;8(11):1481-1489. (Pubitemid 41573659)
82. Everitt BJ, Hutcheson DM, Ersche KD, Pelloux Y, Dalley JW, Robbins TW. The orbital prefrontal cortex and drug addiction in laboratory animals and humans. Ann N Y Acad Sci. 2007;1121:576-597.
83. Ferguson SG, Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. J Subst Abuse Treat. 2009;36(3):235-243.
84. Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs. 2000;59(4):1007-1024. (Pubitemid 30232332)
85. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2004;(4):CD000031.
86. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4(6):215-222. (Pubitemid 30332147)
87. Everitt BJ, Robbins TW. Second-order schedules of drug reinforcement in rats andmonkeys: measurement of reinforcing efficacy and drug-seeking behaviour. Psychopharmacology (Berl). 2000;153(1):17-30. (Pubitemid 32127901)
88. Phillips PE, Stuber GD, Heien ML, Wightman RM, Carelli RM. Subsecond dopamine release promotes cocaine seeking. Nature. 2003;422(6932):614-618. (Pubitemid 36460414)
89. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1-27. (Pubitemid 28326237)
90. Siessmeier T, Kienast T, Wrase J, Larsen JL, Braus DF, Smolka MN, Buchholz HG, Schreckenberger M, Rösch F, Cumming P, Mann K, Bartenstein P, Heinz A. Net influx of plasma 6-[18F]fluoro-L-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli. Eur J Neurosci. 2006;24(1):305-313. (Pubitemid 44050688)
91. Fransson P, Marrelec G. The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: Evidence from a partial correlation network analysis. Neuroimage. 2008;42(3):1178-1184.
92. Molenberghs P, Cunnington R, Mattingley JB. Is the mirror neuron system involved in imitation? a short review and meta-analysis. Neurosci Biobehav Rev. 2009;33(7):975-980.